Now showing items 1-3 of 3

    • Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. 

      Fuchs, CS; Tabernero, J; Tomášek, J; Chau, I; Melichar, B; Safran, H; Tehfe, MA; Filip, D; Topuzov, E; Schlittler, L; Udrea, AA; Campbell, W; Brincat, S; Emig, M; Melemed, SA; Hozak, RR; Ferry, D; Caldwell, CW; Ajani, JA (2016-10)
      Background Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell ...
    • Copy Number Profiling of Brazilian Astrocytomas. 

      Bidinotto, LT; Torrieri, R; Mackay, A; Almeida, GC; Viana-Pereira, M; Cruvinel-Carloni, A; Spina, ML; Campanella, NC; Pereira de Menezes, W; Clara, CA; Becker, AP; Jones, C; Reis, RM (2016-07-07)
      Copy number alterations (CNA) are one of the driving mechanisms of glioma tumorigenesis, and are currently used as important biomarkers in the routine setting. Therefore, we performed CNA profiling of 65 astrocytomas of ...
    • Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. 

      Arnold, D; Fuchs, CS; Tabernero, J; Ohtsu, A; Zhu, AX; Garon, EB; Mackey, JR; Paz-Ares, L; Baron, AD; Okusaka, T; Yoshino, T; Yoon, HH; Das, M; Ferry, D; Zhang, Y; Lin, Y; Binder, P; Sashegyi, A; Chau, I (2017-12)
      Background Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell ...